These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 18385020)

  • 21. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports.
    Sarathy AP; Bourgeois SL; Goodell GG
    J Endod; 2005 Oct; 31(10):759-63. PubMed ID: 16186759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteonecrosis of the jaw after zoledronic acid and denosumab treatment.
    Fusco V; Galassi C; Berruti A; Ciuffreda L; Ortega C; Ciccone G; Angeli A; Bertetto O
    J Clin Oncol; 2011 Jun; 29(17):e521-2; author reply e523-4. PubMed ID: 21537047
    [No Abstract]   [Full Text] [Related]  

  • 23. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
    La Verde N; Bareggi C; Garassino M; Borgonovo K; Sburlati P; Pedretti D; Bianchi C; Perrone S; Mihali D; Cobelli S; Mantica C; Rizzo A; Farina G
    Support Care Cancer; 2008 Nov; 16(11):1311-5. PubMed ID: 18663482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral bisphosphonates and osteonecrosis of the jaw.
    Wynn RL
    Gen Dent; 2007; 55(1):8-10. PubMed ID: 17333956
    [No Abstract]   [Full Text] [Related]  

  • 25. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
    Marx RE
    J Oral Maxillofac Surg; 2003 Sep; 61(9):1115-7. PubMed ID: 12966493
    [No Abstract]   [Full Text] [Related]  

  • 26. Bisphosphonate-related osteonecrosis of the jaws--report of 2 cases and strategies on prevention and management.
    Wong YK; Cheng JC
    Quintessence Int; 2008 Mar; 39(3):195-201. PubMed ID: 18618033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.
    Olson KB; Hellie CM; Pienta KJ
    Urology; 2005 Sep; 66(3):658. PubMed ID: 16140106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Osteonecrosis of the jaw].
    Eriksen EF
    Ugeskr Laeger; 2009 Feb; 171(8):629; author reply 629. PubMed ID: 19291862
    [No Abstract]   [Full Text] [Related]  

  • 29. Yearly zoledronic acid in postmenopausal osteoporosis.
    Chang JT
    N Engl J Med; 2007 Aug; 357(7):713-4; author reply 714-5. PubMed ID: 17703528
    [No Abstract]   [Full Text] [Related]  

  • 30. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
    Wutzl A; Eisenmenger G; Hoffmann M; Czerny C; Moser D; Pietschmann P; Ewers R; Baumann A
    Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Orofacial pain - a presenting symptom of bisphosphonate associated osteonecrosis of the jaws.
    Srinivasan D; Shetty S; Ashworth D; Grew N; Millar B
    Br Dent J; 2007 Jul; 203(2):91-2. PubMed ID: 17660779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characterization might help in preventing osteonecrosis of the jaw.
    Kyrgidis A; Andreadis C
    Clin Cancer Res; 2008 Dec; 14(24):8321; author reply 8321-2. PubMed ID: 19088052
    [No Abstract]   [Full Text] [Related]  

  • 33. Bisphosphonate treatment as a cause of jaw osteonecrosis.
    Kanat O; Ozet A; Ataergin S; Kuzhan O; Arpaci F; Ozturk B; Komurcu S; Ozturk M
    Oral Dis; 2007 May; 13(3):346-7. PubMed ID: 17448221
    [No Abstract]   [Full Text] [Related]  

  • 34. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?
    Ayllon J; Launay-Vacher V; Medioni J; Cros C; Spano JP; Oudard S
    Ann Oncol; 2009 Mar; 20(3):600-1. PubMed ID: 19188135
    [No Abstract]   [Full Text] [Related]  

  • 35. Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern.
    Aguiar Bujanda D; Cabrera Suárez MA; Bohn Sarmiento U; Quintero Pérez S; Aguiar Morales J
    Clin Transl Oncol; 2006 Dec; 8(12):919-21. PubMed ID: 17169767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comment on Pazianas et al.: lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker.
    Yarom N; Elad S
    Osteoporos Int; 2008 Jun; 19(6):849-50; author reply 851. PubMed ID: 18209945
    [No Abstract]   [Full Text] [Related]  

  • 37. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma.
    Diego R; D'Orto O; Pagani D; Agazzi A; Marzano U; Derada Troletti G; Fontanella W; Pignataro L
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103(3):e1-5. PubMed ID: 17197204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
    Brown JJ; Ramalingam L; Zacharin MR
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
    Smith A; Kressley A; Saif MW
    JOP; 2009 Mar; 10(2):212-4. PubMed ID: 19287122
    [No Abstract]   [Full Text] [Related]  

  • 40. Yearly zoledronic acid in postmenopausal osteoporosis.
    Poole KE; Kaptoge S; Reeve J
    N Engl J Med; 2007 Aug; 357(7):711-2; author reply 714-5. PubMed ID: 17703530
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.